Stereotactic Body Radiotherapy for Spinal Metastases: Outcomes and Development of a Risk Assessment Score to Predict Local Tumor Progression - PubMed
6 hours ago
- #risk-assessment
- #SBRT
- #spinal-metastases
- Stereotactic Body Radiotherapy (SBRT) is effective for treating spinal metastases.
- Study analyzed 936 SBRT treatments (600 patients) from 2001-2024.
- Median follow-up was 8 months, and overall survival was 11 months.
- Local tumor progression (LTP) occurred in 13.8% of cases.
- 1-year and 3-year local tumor control rates were 84.2% and 75.1%, respectively.
- Developed an LTP risk scoring system (0-15 scale) using machine learning.
- Risk factors include spinal instability, lytic lesions, misalignment, no prior chemotherapy, and polymetastatic disease.
- LTP incidences: low-risk (2.4%), intermediate-risk (10.2%), high-risk (35.5%).
- Pain response/ stability at 1, 3, and 6 months post-SBRT was 94.4%, 90.6%, and 84.3%.
- Crude risk of grade II/III adverse radiation effects was 12.6%.
- SBRT is safe and effective; risk stratification aids in patient selection.